Results of losmapimod and antioxidants in FSHD

New trial results have recently been published for facioscapulohumeral muscular dystrophy (FHSD). For losmapimod, they show that :

  • in a phase II trial involving 80 people with FSHD1 aged between 18 and 65, the product slowed the progression of the disease compared with placebo,
  • MRI images showed a slowdown in the replacement of muscle cells by fatty tissue in certain muscles,
  • patients reported significant clinical improvements with losmapimod (PROM),
  • no significant difference was observed in muscle expression of DUX4-regulated genes in losmapimod or placebo (primary endpoint of the trial).

With antioxidants, the results of a trial conducted at Montpellier University Hospital (NCT01596803) showed an improvement in muscle volume and quality, muscle strength and antioxidant response in 10 patients compared with 10 others who received a placebo.

 

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Tawil R, Wagner KR, Hamel JI, et al. Lancet Neurol. 2024 Mai.

 

Muscle strength, quantity and quality and muscle fat quantity and their association with oxidative stress in patients with facioscapulohumeral muscular dystrophy: Effect of antioxidant supplementation. Wilson VD, Bommart S, Passerieux E et al. Free Radic Biol Med. 2024 Juil.